Literature DB >> 10819897

Expression of complexin I and II mRNAs and their regulation by antipsychotic drugs in the rat forebrain.

S L Eastwood1, P W Burnet, P J Harrison.   

Abstract

Complexin (cx) I and II are homologous synaptic protein genes which are differentially expressed in mouse and human brain and differentially affected in schizophrenia. We characterized the distribution of cx I and II mRNAs in rat forebrain and examined whether their abundance, or the transcript of the synaptic marker synaptophysin, is affected by 14 days' administration of antipsychotic drugs (haloperidol, chlorpromazine, risperidone, olanzapine, or clozapine). Cx I mRNA predominated in medial habenula, medial septum-diagonal band complex, and thalamus, whereas cx II mRNA was more abundant in most other regions, including isocortex and hippocampus. Within the hippocampus, cx I mRNA was primarily expressed by interneurons and cx II mRNA by granule cells and pyramidal neurons. Localized cx II mRNA signal was seen in the dentate gyrus molecular layer, suggestive of its transport into granule cell dendrites. Antipsychotic treatment produced selective, modest effects on cx mRNA expression. Cx I mRNA was elevated by olanzapine in dorsolateral striatum and frontoparietal cortex, while the abundance of cx II mRNA relative to cx I mRNA was decreased in both areas by olanzapine and haloperidol. Chlorpromazine increased cx II mRNA in frontoparietal cortex and synaptophysin mRNA in dorsolateral striatum. In summary, the data have implications both for understanding the effects of antipsychotic medication on synaptic organization, and for synaptic protein expression studies in patients treated with the drugs. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10819897     DOI: 10.1002/(SICI)1098-2396(20000601)36:3<167::AID-SYN2>3.0.CO;2-D

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  8 in total

Review 1.  Hippocampal neurons in schizophrenia.

Authors:  S Heckers; C Konradi
Journal:  J Neural Transm (Vienna)       Date:  2002-05       Impact factor: 3.575

Review 2.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

3.  Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients.

Authors:  Samantha J Fung; Sinthuja Sivagnanasundaram; Cynthia Shannon Weickert
Journal:  Biol Psychiatry       Date:  2011-01-01       Impact factor: 13.382

4.  Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus.

Authors:  Mathias Zink; Simone Rapp; Peter J Gebicke-Haerter; Fritz A Henn; Johannes Thome
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

5.  Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia.

Authors:  J U Sommer; A Schmitt; M Heck; E L Schaeffer; M Fendt; M Zink; K Nieselt; S Symons; G Petroianu; A Lex; M Herrera-Marschitz; R Spanagel; P Falkai; P J Gebicke-Haerter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-14       Impact factor: 5.270

Review 6.  [Structural and functional brain changes in schizophrenic disorders. Indications of early neuronal developmental disturbances?].

Authors:  P Kalus; P Falkai; A Heinz
Journal:  Nervenarzt       Date:  2008-03       Impact factor: 1.214

7.  Interneuron Transcriptional Dysregulation Causes Frequency-Dependent Alterations in the Balance of Inhibition and Excitation in Hippocampus.

Authors:  Aundrea F Bartley; Elizabeth K Lucas; Lillian J Brady; Qin Li; John J Hablitz; Rita M Cowell; Lynn E Dobrunz
Journal:  J Neurosci       Date:  2015-11-18       Impact factor: 6.167

8.  Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.

Authors:  Sharon L Eastwood; Paul J Harrison
Journal:  Neuropsychopharmacology       Date:  2007-05-16       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.